# Meta-Reflection: Zepbound Q4 2025 Revenue Forecast

## Executive Summary
- **Question**: Zepbound Q4 2025 global revenue
- **Final Forecast**: Median ~$5,200M, 80% CI: $4,500M - $5,700M
- **Approach**: Historical trend analysis, YoY growth patterns, sequential growth patterns

## Research Audit

### Searches that worked well:
1. Direct investor relations pages from Eli Lilly - got exact quarterly revenue figures
2. Search for quarterly earnings results across 2025

### Key findings:
- Q1 2025: $2,310M
- Q2 2025: $3,381M  
- Q3 2025: $3,588.1M
- YTD through Q3: $9,279M
- Q4 2024: $1,910M (baseline for YoY comparison)

### Data gaps:
- Could not find specific analyst consensus estimates for Q4 2025 Zepbound revenue
- Most searches returned company press releases rather than analyst reports

## Reasoning Quality Check

### Strongest evidence FOR my central estimate (~$5,200M):
1. Multiple estimation methods converge: Q3→Q4 2024 pattern gives $5,439M, Q3 YoY continuation gives $5,439M
2. Historical Q4 strength is consistent (51.6% sequential growth in 2024)
3. LillyDirect channel maintains demand despite CVS formulary removal

### Strongest argument AGAINST my forecast:
- YoY growth could decelerate faster than expected as base effects normalize
- CVS formulary exclusion (July 2025) may have larger Q4 impact than Q3
- Pricing pressure could intensify

### Calibration check:
- Question type: Measurement (future value of known metric)
- Applied appropriate uncertainty: ±$600M around median for 80% CI
- Distribution is slightly right-skewed given potential upside from demand outpacing expectations

## Subagent Decision
Did not use subagents - this was a straightforward data retrieval and trend analysis task. Direct searches and WebFetch for investor relations pages were sufficient.

## Tool Effectiveness
- **Worked well**: mcp__search__web_search, WebFetch for Lilly investor pages, mcp__sandbox__execute_code
- **Tool failures**: WebFetch for FiercePharma and BioPharma Dive (403 errors)
- **Empty results**: Several searches for analyst estimates returned no results

## Process Feedback
- The quarterly earnings data was well-documented and accessible
- Would have benefited from dedicated financial data tools (analyst estimates, consensus data)
- Code execution for trend analysis was helpful for systematizing the estimates

## Calibration Tracking
- 80% CI: $4,500M - $5,700M
- 90% CI: $4,000M - $6,100M
- Would move estimate up if: Lilly announces supply improvements, new major payor coverage
- Would move estimate down if: Significant pricing cuts, competitive drug approvals
---

## Programmatic Metrics

*Auto-generated - do not edit manually*

- **Post ID**: 41747
- **Question ID**: 41487
- **Session Duration**: 572.6s (9.5 min)
- **Cost**: $1.0769
- **Tokens**: 12,366 total (111 in, 12,255 out)
  - Cache: 585,800 read, 52,314 created
- **Log File**: `logs/41747_20260205_073357/20260205_073358.log`

### Tool Calls

- **Total**: 20 calls
- **Errors**: 0 (0.0%)

| Tool | Calls | Errors | Avg Time |
|------|-------|--------|----------|
| execute_code | 1 | 0 | 239ms |
| notes | 1 | 0 | 2ms |
| stock_history | 1 | 0 | 426ms |
| web_search | 17 | 0 | 21609ms |

### Sources Consulted

- https://investor.lilly.com/news-releases/news-release-details/lilly-reports-t...
- https://investor.lilly.com/news-releases/news-release-details/lilly-reports-f...
- https://investor.lilly.com/news-releases/news-release-details/lilly-reports-f...
- https://investor.lilly.com/news-releases/news-release-details/lilly-reports-s...
- https://www.fiercepharma.com/pharma/cvs-formulary-hitch-doesnt-dent-lillys-ze...
- https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound...
- https://www.drugdiscoverytrends.com/lilly-is-set-to-lead-pharma-in-2026-but-c...